Scientific Presentations

Presentation at the Vaccines Summit-2023 entitled “Robust Immunogenicity and Protection with PlaCCine: A Novel DNA Vaccine Delivered with a Functionalized Polymeric Delivery System” by Dr. Jean Boyer, Imunon’s Vice President of Research & Development

Presentation at the 3rd International Vaccine Congress entitled “A DNA-based Vaccine Technology Independent of Virus or Device” by Dr. Khursheed Anwer, IMUNON’s Chief Science Officer

Virtual R&D Day

IMUNON’s CEO Presents Business Overview to Investors and Senior Biopharmaceutical Professionals at the BIO 2023 International Convention

Oral Presentation of PlaCCine Preclinical Data at the 2023 Viruses and Cells – Gordon Research Conference by Dr. Khursheed Anwer, IMUNON’s Chief Science Officer

Poster Presentation at the American Association for Cancer Research Annual Meeting entitled “Efficacy of IMNN-001, an Interleukin-12 Immune Gene Therapy, at Different Dose Frequencies” by Dr. Jean Boyer, IMUNON’s Vice President – Preclinical R&D

PLACCINE: Nucleic Acid Vaccine Platform

Presentation at the World Vaccine & Immunotherapy Congress entitled “PLACCINE Nucleic Acid Vaccine Platform – Preclinical Proof of Concept Using a SARS-CoV-2 pDNA Construct” by Dr. Khursheed Anwer, IMUNON’s Chief Science Officer

Presentation at the 2022 World Vaccine Congress entitled “Novel DNA Approaches for Cancer Immunotherapies and Multivalent Infectious Disease Vaccines” by Dr. Khursheed Anwer, Celsion’s Chief Science Officer

“Phase Ib Trial Efficacy Estimates via a Clinical Trial Synthetic Control Arm” at the 2022 Annual Meeting of the American Association for Cancer Research (AACR) in New Orleans, LA

Poster Presentation at Society of Gynecologic Oncology (SGO) Virtual Annual Meeting on Women’s Cancer_March 19-26, 2021

Expert Call – Ovarian Cancer Treatment Landscape and Emerging Opportunities Oppenheimer & Co. Inc. Conference Call

Presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium Entitled “Phase I study of IL-12 plasmid administered in combination with NAC in patients with advanced stage ovarian cancer” by Dr. Premal H. Thaker, M.D., M.S.

Publication in Future Oncology – GEN-1 immunotherapy for the treatment of ovarian cancer, Premal H. Thaker, Nicholas Borys, Jason Fewell & Khursheed Anwer

KoL Lunch Presentation by Dr. Premal Thaker titled “Ovarian Cancer: New Horizons and Treatments”

Presentation at the American Association of Cancer Research (AACR) Special Conference entitled "Addressing Critical Questions in Ovarian Cancer Research and Treatment" by Dr. Khursheed Anwer, Celsion's executive vice president and chief scientific officer

Presentation at the American Society of Clinical Oncology (ASCO) - Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium by Khursheed Anwer, Ph.D. (Celsion's executive vice president and chief science officer) entitled "Immunologic

Presentation at the American Society of Clinical Oncology (ASCO) - Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium by Khursheed Anwer, Ph.D. (Celsion's executive vice president and chief science officer) entitled "Phase I st

Presentation at the 2016 American Association of Cancer Research (AACR) Annual Meeting during the Drug Delivery Session by Dr. Jason Fewell entitled "Interlukin-12 Gene therapy in Combination with Bevacizumab and PEGylated Liposomal Doxorubicin for Treatm

A Phase I Study of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Pegylated Liposomal Doxorubicin) in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Pr

Presentation at the Molecular Medicine TRI-Conference on February 20, 2015 by Dr. Khursheed Anwer titled "Development of a Novel IL-12 DNA-based Immunotherapy in Combination with Chemotherapy for Treatment of Advanced Ovarian Cancer."